HEK-293 Transfection Reagent (Epithelial Kidney Cells)
Transfection Reagent for HEK-293 Cells (Epithelial Kidney Cells, CRL-1573)
Two component formulation enhances lipid mediated transfection efficiency
Optimized easy-to-use transfection protocol provided for transfection of siRNA, DNA, mRNA, and microRNA
Kit includes Transfection Enhancer reagent and recommended transfection protocol
High transfection efficacy in the presence of serum
Expand your RNAi application with a reagent optimized for delivery of both siRNA and plasmid
Reproducible transfection results
Works well for standard reverse transfection and high-throughput applications
Developed and manufactured by Altogen Biosystems
Reagent exhibits at least 90% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.
Transfection Protocol and MSDS:
Download Altogen Biosystems HEK-293 Transfection Protocol: [PDF]
Download MSDS: [PDF]
HEK-293 Cell Line:
HEK-293 (human epithelial kidney cells) were originally derived in 1977 from human embryonic kidney cells transformed with sheared adenovirus 5 DNA grown in tissue culture. The transformation incorporated approximately 4.5 kilobases from the viral genome into human chromosome 19 of the HEK cells. HEK has been described as being a cellular test tube. These cells were developed from embryonic kidney cells, and are useful in a variety of molecular and biological research, many of which have medical applications. HEK-293 cells are widely used to produce therapeutic proteins and viruses for gene therapy.
Figure 1. SiRNAs targeting Lamin A/C mRNA or non-silencing control siRNA were transfected into HEK-293 cells following the recommended protocol. At 48 hours post-transfection the cells were analyzed by qRT-PCR for gene expression levels. 18S rRNA levels were used to normalize the Lamin A/C data. Values are normalized to untreated sample. Data are means ± SD (n=3).
Selected in vivo transfection product citations (ALTOGEN® IN VIVO Transfection Kits used in the following publications):
- Am J Pathology. 2010 177(4):1870-80. Role of ocular complement factor H in a murine model ... Lyzogubov et al [PDF]
- Jounal of Biological Chemistry. 2012 287(4):2907. Chaperoning of mutant p53 protein ... Gogna et al [PDF]
- PLoS Pathogens. 2012 8(8) Uridine composition of the poly-U/UC tract of HCV RNA ... Schnell et al [PDF]
- J Proteome Res. 2012(11) Retinal proteome analysis in a mouse model of oxygen-induced ... Kim et al [PDF]
- J Transl Med. 2010 15;8:133. Prevention of hyperglycemia-induced myocardial apoptosis ... Zhang et al [PDF]
Altogen Biosystems is a life sciences company that offers cell type-specific and pre-optimized transfection products, elecroporation kits, and in vivo delivery reagents (peg-liposome, nanoparticle, lipid, and polymer-based; and tissue targeted: liver, pancreas, kidney). Advanced formulation of reagents and optimized transfection protocols provide efficient intracellular delivery of protein, DNA, mRNA, shRNA and siRNA molecules. Read more about transfection technology at Altogen's Transfection Resource.
Altogen Research Services:
Altogen Labs is a GLP compliant laboratory that provides preclinical contract research services (CRO). Pharma and biotechnology services include: transient and stable transfection (development of stable cell lines), liposome encapsulation (proteins, DNA, mRNA, siRNA), A-to-Z RNAi services, in vivo and in vitro toxicology, xenograft animal models, assay development, cell banking and cryopreservation services.